_id
6910551cccc777a4e85d55b0
Ticker
CRSP
Name
Crispr Therapeutics AG
Exchange
NASDAQ
Address
Baarerstrasse 14, Zug, Switzerland, 6300
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.crisprtx.com
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Last Close
58.09
Volume
1406593
Current Price
56.68
Change
-2.42726803236358
Last Updated
2025-11-29T11:52:25.927Z
Image
-
Ipo Date
2016-10-19T00:00:00.000Z
Market Cap
5095703552
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9189068181818182
Sentiment Sources
44
Rating
3.9643
Target Price
81.3333
Strong Buy
12
Buy
5
Hold
10
Sell
0
Strong Sell
1
Current Quarter
2025-09-30
Revenue
889000
Cost Of Revenue
64693000
Gross Profit
-63804000
Operating Expenses
68255000
Operating Income
-132059000
Interest Expense
-
Pretax Income
-105822000
Net Income
-106441000
Eps
-1.1657697512249476
Dividends Per Share
-
Shares Outstanding
95300233
Income Tax Expense
619000
EBITDA
-101389000
Operating Margin
-14854.780652418447
Total Other Income Expense Net
26237000
Cash
286497000
Short Term Investments
1629213000
Receivables
0
Inventories
-
Total Current Assets
1929092000
Property Plant Equipment
255490000
Total Assets
2245308000
Payables
11798000
Short Term Debt
18256000
Long Term Debt
-
Total Liabilities
329326000
Equity
1915982000
Depreciation
4433000
Change In Working Capital
10909000
Cash From Operations
-84634000
Capital Expenditures
74000
Cash From Investing
-119226000
Cash From Financing
296766000
Net Change In Cash
92879000
PE
-
PB
2.7010621713356384
ROE
-5.555427973749231
ROA
-4.740596835712517
FCF
-84708000
Fcf Percent
-95.28458942632172
Piotroski FScore
1
Health Score
35
Deep Value Investing Score
3.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
5.3
Garp Investing Score
2.5
Growth Investing Score
1
Momentum Investing Score
4.5
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
4.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
889000
Quarters > 0 > income Statement > cost Of Revenue
64693000
Quarters > 0 > income Statement > gross Profit
-63804000
Quarters > 0 > income Statement > operating Expenses
68255000
Quarters > 0 > income Statement > operating Income
-132059000
Quarters > 0 > income Statement > interest Expense
-
Quarters > 0 > income Statement > pretax Income
-105822000
Quarters > 0 > income Statement > net Income
-106441000
Quarters > 0 > income Statement > eps
-1.1657697512249476
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
91305337
Quarters > 0 > income Statement > income Tax Expense
619000
Quarters > 0 > income Statement > EBITDA
-101389000
Quarters > 0 > income Statement > operating Margin
-14854.780652418447
Quarters > 0 > income Statement > total Other Income Expense Net
26237000
Quarters > 0 > balance Sheet > cash
286497000
Quarters > 0 > balance Sheet > short Term Investments
1629213000
Quarters > 0 > balance Sheet > receivables
0
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
1929092000
Quarters > 0 > balance Sheet > property Plant Equipment
255490000
Quarters > 0 > balance Sheet > total Assets
2245308000
Quarters > 0 > balance Sheet > payables
11798000
Quarters > 0 > balance Sheet > short Term Debt
18256000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
329326000
Quarters > 0 > balance Sheet > equity
1915982000
Quarters > 0 > cash Flow > net Income
-106441000
Quarters > 0 > cash Flow > depreciation
4433000
Quarters > 0 > cash Flow > change In Working Capital
10909000
Quarters > 0 > cash Flow > cash From Operations
-84634000
Quarters > 0 > cash Flow > capital Expenditures
74000
Quarters > 0 > cash Flow > cash From Investing
-119226000
Quarters > 0 > cash Flow > cash From Financing
296766000
Quarters > 0 > cash Flow > net Change In Cash
92879000
Quarters > 0 > ratios > PE
-1.1657697512249476
Quarters > 0 > ratios > PB
2.7010621713356384
Quarters > 0 > ratios > ROE
-5.555427973749231
Quarters > 0 > ratios > ROA
-4.740596835712517
Quarters > 0 > ratios > FCF
-84708000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-95.28458942632172
Quarters > 0 > health Score
35
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
892000
Quarters > 1 > income Statement > cost Of Revenue
45153000
Quarters > 1 > income Statement > gross Profit
-45153000
Quarters > 1 > income Statement > operating Expenses
184171000
Quarters > 1 > income Statement > operating Income
-229324000
Quarters > 1 > income Statement > interest Expense
-
Quarters > 1 > income Statement > pretax Income
-207257000
Quarters > 1 > income Statement > net Income
-208549000
Quarters > 1 > income Statement > eps
-2.3951963076932974
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
87069690
Quarters > 1 > income Statement > income Tax Expense
1292000
Quarters > 1 > income Statement > EBITDA
-224675000
Quarters > 1 > income Statement > operating Margin
-25708.968609865467
Quarters > 1 > income Statement > total Other Income Expense Net
22067000
Quarters > 1 > balance Sheet > cash
197132000
Quarters > 1 > balance Sheet > short Term Investments
1527619000
Quarters > 1 > balance Sheet > receivables
0
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
1733666000
Quarters > 1 > balance Sheet > property Plant Equipment
262567000
Quarters > 1 > balance Sheet > total Assets
2029711000
Quarters > 1 > balance Sheet > payables
9753000
Quarters > 1 > balance Sheet > short Term Debt
18027000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
318586000
Quarters > 1 > balance Sheet > equity
1711125000
Quarters > 1 > cash Flow > net Income
-208549000
Quarters > 1 > cash Flow > depreciation
4649000
Quarters > 1 > cash Flow > change In Working Capital
-16512000
Quarters > 1 > cash Flow > cash From Operations
-113880000
Quarters > 1 > cash Flow > capital Expenditures
117000
Quarters > 1 > cash Flow > cash From Investing
69977000
Quarters > 1 > cash Flow > cash From Financing
2258000
Quarters > 1 > cash Flow > net Change In Cash
-41565000
Quarters > 1 > ratios > PE
-2.3951963076932974
Quarters > 1 > ratios > PB
2.8841318017094015
Quarters > 1 > ratios > ROE
-12.187829644239901
Quarters > 1 > ratios > ROA
-10.274812522570947
Quarters > 1 > ratios > FCF
-113997000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-127.79932735426009
Quarters > 1 > health Score
35
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
865000
Quarters > 2 > income Statement > cost Of Revenue
57509000
Quarters > 2 > income Statement > gross Profit
-56644000
Quarters > 2 > income Statement > operating Expenses
91780000
Quarters > 2 > income Statement > operating Income
-148424000
Quarters > 2 > income Statement > interest Expense
-
Quarters > 2 > income Statement > pretax Income
-134887000
Quarters > 2 > income Statement > net Income
-135996000
Quarters > 2 > income Statement > eps
-1.5824764436798686
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
85938720
Quarters > 2 > income Statement > income Tax Expense
1109000
Quarters > 2 > income Statement > EBITDA
-143688000
Quarters > 2 > income Statement > operating Margin
-17158.84393063584
Quarters > 2 > income Statement > total Other Income Expense Net
13537000
Quarters > 2 > balance Sheet > cash
235184000
Quarters > 2 > balance Sheet > short Term Investments
1620101000
Quarters > 2 > balance Sheet > receivables
0
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
1867611000
Quarters > 2 > balance Sheet > property Plant Equipment
269703000
Quarters > 2 > balance Sheet > total Assets
2166102000
Quarters > 2 > balance Sheet > payables
13064000
Quarters > 2 > balance Sheet > short Term Debt
17506000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
336942000
Quarters > 2 > balance Sheet > equity
1829160000
Quarters > 2 > cash Flow > net Income
-135996000
Quarters > 2 > cash Flow > depreciation
4736000
Quarters > 2 > cash Flow > change In Working Capital
54848000
Quarters > 2 > cash Flow > cash From Operations
-53947000
Quarters > 2 > cash Flow > capital Expenditures
206000
Quarters > 2 > cash Flow > cash From Investing
-19755000
Quarters > 2 > cash Flow > cash From Financing
10588000
Quarters > 2 > cash Flow > net Change In Cash
-63073000
Quarters > 2 > ratios > PE
-1.5824764436798686
Quarters > 2 > ratios > PB
2.6629746165452994
Quarters > 2 > ratios > ROE
-7.434888145378206
Quarters > 2 > ratios > ROA
-6.278374702576333
Quarters > 2 > ratios > FCF
-54153000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-62.60462427745665
Quarters > 2 > health Score
35
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
35000000
Quarters > 3 > income Statement > cost Of Revenue
4151000
Quarters > 3 > income Statement > gross Profit
35000000
Quarters > 3 > income Statement > operating Expenses
99588000
Quarters > 3 > income Statement > operating Income
-64588000
Quarters > 3 > income Statement > interest Expense
-
Quarters > 3 > income Statement > pretax Income
-36611000
Quarters > 3 > income Statement > net Income
-37311000
Quarters > 3 > income Statement > eps
-0.43656849649839563
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
85464252
Quarters > 3 > income Statement > income Tax Expense
700000
Quarters > 3 > income Statement > EBITDA
-59746000
Quarters > 3 > income Statement > operating Margin
-184.53714285714287
Quarters > 3 > income Statement > total Other Income Expense Net
27977000
Quarters > 3 > balance Sheet > cash
298257000
Quarters > 3 > balance Sheet > short Term Investments
1605569000
Quarters > 3 > balance Sheet > receivables
25000000
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
1937132000
Quarters > 3 > balance Sheet > property Plant Equipment
277554000
Quarters > 3 > balance Sheet > total Assets
2242034000
Quarters > 3 > balance Sheet > payables
14709000
Quarters > 3 > balance Sheet > short Term Debt
17288000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
309954000
Quarters > 3 > balance Sheet > equity
1932080000
Quarters > 3 > cash Flow > net Income
-37311000
Quarters > 3 > cash Flow > depreciation
4842000
Quarters > 3 > cash Flow > change In Working Capital
-24354000
Quarters > 3 > cash Flow > cash From Operations
-50031000
Quarters > 3 > cash Flow > capital Expenditures
254000
Quarters > 3 > cash Flow > cash From Investing
105828000
Quarters > 3 > cash Flow > cash From Financing
16876000
Quarters > 3 > cash Flow > net Change In Cash
72586000
Quarters > 3 > ratios > PE
-0.43656849649839563
Quarters > 3 > ratios > PB
2.5072014633762576
Quarters > 3 > ratios > ROE
-1.9311312160987124
Quarters > 3 > ratios > ROA
-1.664158527479958
Quarters > 3 > ratios > FCF
-50285000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-1.4367142857142856
Quarters > 3 > health Score
34
Valuation > metrics > PE
-1.1657697512249476
Valuation > metrics > PB
2.7010621713356384
Valuation > final Score
80
Valuation > verdict
Fair
Profitability > metrics > ROE
-5.555427973749231
Profitability > metrics > ROA
-5.517673599807578
Profitability > metrics > Net Margin
-119.73115860517436
Profitability > final Score
0
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.17188366070244918
Risk > metrics > Interest Coverage
-29.78998420933905
Risk > final Score
-59
Risk > verdict
High
Liquidity > metrics > Current Ratio
64.187529114261
Liquidity > metrics > Quick Ratio
64.187529114261
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
80
Prev Valuations > 1
80
Prev Valuations > 2
80
Prev Profitabilities > 0
0
Prev Profitabilities > 1
0
Prev Profitabilities > 2
0
Prev Risks > 0
7
Prev Risks > 1
-7
Prev Risks > 2
49
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:21:58.826Z
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Hold" from Analysts MarketBeat
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
BUY
Target Price:
$81.3333
Analyst Picks
Strong Buy
12
Buy
5
Hold
10
Sell
0
Strong Sell
1
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 102.66% of the total shares of Crispr Therapeutics AG
1.
ARK Investment Management LLC(11.1958%)
since
2025/06/30
2.
ARK Disruptive Innovation Full Composite(7.7447%)
since
2025/06/30
3.
ARK Innovation ETF(7.2542%)
since
2025/08/28
4.
BlackRock Inc(6.67%)
since
2025/06/30
5.
Capital Research & Mgmt Co - Division 3(6.1503%)
since
2025/06/30
6.
T. Rowe Price Investment Management,Inc.(4.0495%)
since
2025/06/30
7.
State Street Corp(3.596%)
since
2025/06/30
8.
UBS Group AG(3.1265%)
since
2025/06/30
9.
Orbis Allan Gray Ltd(3.0396%)
since
2025/06/30
10.
Sumitomo Mitsui Trust Group Inc(2.6551%)
since
2025/06/30
11.
Amova Asset Management Americas, Inc(2.6545%)
since
2025/06/30
12.
Vanguard Group Inc(2.5267%)
since
2025/06/30
13.
American Funds New Perspective A(2.3599%)
since
2025/06/30
14.
Capital Group New Perspective Comp(2.3599%)
since
2025/06/30
15.
Geode Capital Management, LLC(2.278%)
since
2025/06/30
16.
ARK Genomic Revolution(2.2616%)
since
2025/06/30
17.
iShares Russell 2000 ETF(2.1955%)
since
2025/08/31
18.
FMR Inc(2.1211%)
since
2025/06/30
19.
ARK Genomic Revolution ETF(2.0269%)
since
2025/08/28
20.
American Funds SMALLCAP World A(1.8118%)
since
2025/06/30
21.
NEA Management Company, LLC(1.7458%)
since
2025/06/30
22.
Two Sigma Investments LLC(1.6998%)
since
2025/06/30
23.
T. Rowe Price US Mid-Cap Growth Equity(1.6394%)
since
2025/06/30
24.
Bank of America Corp(1.5925%)
since
2025/06/30
25.
SPDR® S&P Biotech ETF(1.5344%)
since
2025/08/31
26.
EcoR1 Capital, LLC(1.5275%)
since
2025/06/30
27.
Two Sigma Advisers, LLC(1.4785%)
since
2025/06/30
28.
Amova ARK Disruptive Innovation A USD(1.2797%)
since
2025/07/31
29.
T. Rowe Price Mid-Cap Growth(1.2369%)
since
2025/07/31
30.
SR ONE CAPITAL MANAGEMENT, LP(1.1533%)
since
2025/06/30
31.
Amova ARK Pstv Chg Innovt P JPY Acc(1.0668%)
since
2025/07/31
32.
UBS Asset Mgmt Americas Inc(1.0607%)
since
2025/06/30
33.
Capital Group Growth Fnd of Amer Comp(1.0527%)
since
2025/06/30
34.
American Funds Growth Fund of Amer A(1.0527%)
since
2025/06/30
35.
Fidelity Growth Compy Commingled Pl S(1.0461%)
since
2025/07/31
36.
Charles Schwab Investment Management Inc(1.0261%)
since
2025/06/30
37.
Vanguard Institutional Extnd Mkt Idx Tr(1.0202%)
since
2025/07/31
38.
Fidelity Small Cap Index(0.9132%)
since
2025/06/30
39.
iShares Russell 2000 Value ETF(0.8009%)
since
2025/08/31
40.
Fidelity Growth Company Fund(0.6566%)
since
2025/07/31
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.